coteau ARQ.

SPTX

Seaport Therapeutics, Inc.
$20.61
−$0.15 (0.72%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-25%-8%+9%+26%+43%May 1Oct 23Jul 2752w high $28.3852w low $14.85
SPTXSPY
Wall St. Highest PT $50.00 (+142.6%) Wall St. Avg PT $37.00 (+79.5%)
$15$25$35$45$55POC $17Hi $50Avg $37
Underwater Drawdown %Max DD -42.2%Current -26.0%
0.0%-42.2%
Relative Strength vs SPY-2.1% vs SPYUnderperforming
+39%0%-39%
1W
+$2.78 (15.59%)
1M
−$0.68 (3.19%)
3M
−$0.49 (2.32%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
8 analysts · mean score 1.33
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$20.61
Average target$37.00
+$16.39 (+79.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$28.00
Median$37.00
High$50.00
12-month Wall Street target range
Recent analyst rating changes · 12
Initiated
2026-10-14 · Canaccord Genuity started covering SPTX at Buy
Reiterated
2026-10-08 · HC Wainwright & Co. reiterated Buy on SPTX
Initiated
2026-09-25 · Raymond James started covering SPTX at Strong Buy
Reiterated
2026-09-10 · HC Wainwright & Co. reiterated Buy on SPTX
Initiated
2026-08-26 · Jones Trading started covering SPTX at Buy
Reiterated
2026-08-20 · HC Wainwright & Co. reiterated Buy on SPTX
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$1.1B
P/E (next 12 months, estimated)-8.2
52-week range$14.85 – $28.38
Dividend yieldNo dividend
Analyst consensusStrong Buy (8)
Average analyst price target$37.00 (+80%)

What they do

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for SPTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

SPTX earningsNext report in 18 days
Next report
Thu Nov 12, 2026Before the open
EPS consensus-$0.56 range -$0.63–-$0.50
Revenue consensus$0 7 analysts
Last 2 quarters · EPS vs estimate
Aug 3, 2026-$1.78est -$0.66−171.2%Below estimates
Jun 8, 2026-$10.34est -$3.88−166.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 03:13:00 ET
26-0626-08-10.340.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-03-31$0–
2025-03-31$0–

News & catalysts

More news
Canaccord Genuity Initiates Coverage on Seaport Therapeutics With Buy Rating, $28 Price Target
MT Newswires · Oct 14
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Business Wire · Oct 09
Seaport Therapeutics Says Drug Potentially Reduces Liver Impact of Depression Treatment
MT Newswires · Oct 09
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Business Wire · Oct 09
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Business Wire · Oct 07
Rating changes
Initiated
2026-10-14 · Canaccord Genuity started covering SPTX at Buy
Reiterated
2026-10-08 · HC Wainwright & Co. reiterated Buy on SPTX
Initiated
2026-09-25 · Raymond James started covering SPTX at Strong Buy
Reiterated
2026-09-10 · HC Wainwright & Co. reiterated Buy on SPTX
Initiated
2026-08-26 · Jones Trading started covering SPTX at Buy
Reiterated
2026-08-20 · HC Wainwright & Co. reiterated Buy on SPTX

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 03:13:00 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026